Shares of Cleveland BioLabs, Inc. (NASDAQ:CBLI) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.09 and traded as high as $2.53. Cleveland BioLabs shares last traded at $2.38, with a volume of 183,508 shares changing hands.
Separately, ValuEngine lowered shares of Cleveland BioLabs from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd.
The business has a fifty day moving average price of $2.36 and a two-hundred day moving average price of $2.09.
Cleveland BioLabs (NASDAQ:CBLI) last issued its earnings results on Friday, May 15th. The biotechnology company reported ($0.05) earnings per share for the quarter. The business had revenue of $0.16 million during the quarter. Cleveland BioLabs had a negative net margin of 220.62% and a negative return on equity of 169.32%.
About Cleveland BioLabs (NASDAQ:CBLI)
Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines.
Featured Story: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.